The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension

Autor: Areti Hitoglou-Makedou, Anastasios N. Lasaridis, P. Sarafidis, Achilleas A. Tourkantonis, Panagiotis Stafylas, Peter M. Nilsson, Kiriakos A. Kazakos, Tzant F. Mouslech, John G. Yovos
Rok vydání: 2005
Předmět:
Zdroj: Metabolism. 54:1236-1242
ISSN: 0026-0495
DOI: 10.1016/j.metabol.2005.04.010
Popis: Thiazolidinediones are antidiabetic agents that decrease insulin resistance. Emerging evidence indicates that they present beneficial effects for the vasculature beyond glycemic control. The aim of this open-label observational study was to determine the effect of the thiazolidinedione rosiglitazone on novel cardiovascular risk factors, namely, lipoprotein(a) [Lp(a)], C-reactive protein (CRP), homocysteine, and fibrinogen in patients with type 2 diabetes and hypertension. A total of 40 type 2 diabetic patients already on treatment with 15 mg of glibenclamide daily and with poorly controlled or newly diagnosed hypertension were included in the study. Twenty of them received 4 mg of rosiglitazone daily as added-on therapy, whereas the rest remained on the preexisting antidiabetic treatment for 26 weeks. At baseline and the end of the study, subjects gave blood tests for the determination of Lp(a), CRP, homocysteine, fibrinogen, serum lipids, apolipoprotein (apo) A-I, and apo B. At the end of the study, rosiglitazone treatment was associated with significant reductions in Lp(a) (10.5 [8.9-54.1] to 9.8 [8.0-42.0] mg/dL, P
Databáze: OpenAIRE
Externí odkaz: